Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Cadrenal Therapeutics Inc CVKD

Healthcare Biotechnology
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.


NDAQ:CVKD - Post by User

Cadrenal Therapeutics Inc
<< Previous
 Bullboard Posts
User Avatar Image
(14)
•••
  • MasterJediJazz2X
Post by MasterJediJazz2on May 13, 2025 11:09am
19 Views
Post# 36571666

$CVKD $13.8796 +3.73% in the news -Cadrenal Therapeutics

$CVKD $13.8796 +3.73% in the news -Cadrenal Therapeutics $CVKD $13.8796 +3.73% in the news as Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update https://finance.yahoo.com/news/cadrenal-therapeutics-reports-first-quarter-120000712.html

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities